RxSight, Inc. (NASDAQ:RXST) Stock Has Average Price Target of $8.17

Posted by Stanley Muller on Oct 31st, 2026

Shares of RxSight, Inc. (NASDAQ:RXST – Get Free Report) have received an average rating of “Reduce” from the twelve analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $8.17.

Several research analysts recently issued reports on RXST shares. UBS Group increased their price target on shares of RxSight from $5.50 to $6.30 and gave the stock a “neutral” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of RxSight in a research note on Tuesday, September 8th. Stifel Nicolaus decreased their price objective on RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Bank of America lowered their price objective on RxSight from $6.50 to $5.50 and set an “underperform” rating on the stock in a research note on Tuesday, September 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of RxSight in a research note on Tuesday, July 7th.

Check Out Our Latest Research Report on RXST

Insider Activity at RxSight

In other RxSight news, CFO Mark Wilterding sold 7,765 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $54,044.40. Following the sale, the chief financial officer directly owned 25,049 shares in the company, valued at $174,341.04. This represents a 23.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ronald M. Md Kurtz sold 5,100 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the transaction, the insider owned 71,775 shares of the company’s stock, valued at $499,554. This represents a 6.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,947 shares of company stock valued at $117,951 in the last 90 days. 10.05% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On RxSight

Several institutional investors and hedge funds have recently made changes to their positions in RXST. BlackRock Inc. acquired a new position in shares of RxSight in the 2nd quarter worth approximately $27,910,000. Bank of America Corp DE grew its position in RxSight by 30.3% during the 1st quarter. Bank of America Corp DE now owns 1,210,039 shares of the company’s stock worth $7,454,000 after acquiring an additional 281,426 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in RxSight by 761.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company’s stock worth $6,969,000 after acquiring an additional 1,000,000 shares during the last quarter. Grandeur Peak Global Advisors LLC acquired a new stake in RxSight during the 2nd quarter valued at $3,482,000. Finally, Deutsche Bank AG acquired a new stake in RxSight during the 2nd quarter valued at $2,604,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Price Performance

RXST opened at $4.87 on Wednesday. The company has a market capitalization of $202.54 million, a P/E ratio of -4.31 and a beta of 1.15. The firm’s fifty day moving average price is $5.39 and its two-hundred day moving average price is $6.39. RxSight has a fifty-two week low of $4.40 and a fifty-two week high of $13.22.

RxSight (NASDAQ:RXST – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $32.55 million. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. On average, equities research analysts expect that RxSight will post -1.03 EPS for the current fiscal year.

RxSight Company Profile

(Get Free Report)

RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.

Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs.